ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Blue Faery Recognizes Excellence in Liver Cancer Research





$25,000 Grant Awarded to Support Innovative Hepatocellular Carcinoma Studies

LOS ANGELES, CA, April 08, 2025 /24-7PressRelease/ -- Blue Faery: The Adrienne Wilson Liver Cancer Association announces the Blue Faery Award (BFA) for Excellence in Liver Cancer Research recipient. Primary liver cancer, also known as Hepatocellular Carcinoma (HCC), remains the third leading cause of cancer-related deaths worldwide. Blue Faery established the award to honor medical professionals conducting groundbreaking research to improve patient outcomes.

The winner, Dr. Mark Yarchoan, said, "I am deeply honored to receive the Blue Faery Award, which not only supports liver cancer research but also highlights the strength of the community driving progress in this field."

Mark Yarchoan, M.D., is an Associate Professor of Medical Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland. He leads an NCI-funded laboratory focused on understanding and overcoming barriers to effective antitumor immunity. Dr. Yarchoan is at the forefront of advancing immunotherapy treatments for liver cancers and has served as Principal Investigator on several notable clinical trials, including the first clinical trials of a personalized neoantigen vaccine for HCC and neoadjuvant anti-PD1 immunotherapy in HCC. A recognized clinical expert in hepatobiliary cancers, he participates in international guideline committees for liver cancers for the American Association for the Study of Liver Diseases and the American Society of Clinical Oncology.

President Andrea Wilson Woods stated, "Recognizing and supporting innovative HCC research is crucial in the fight against this devastating disease. Liver cancer is one of the most common and deadliest cancers worldwide, and we are committed to advancing research that makes a real difference." Andrea founded Blue Faery in memory of her sister, Adrienne, who passed away from HCC at 15. The organization announces the annual award winner on Adrienne's birthday—this year, she would have turned 39.

Blue Faery's mission is to prevent, treat, and cure primary liver cancer through research, education, and advocacy. Blue Faery hosts an online Liver Cancer Community for patients and caregivers. Blue Faery provides free comprehensive patient education with its Patient Resource Guides for Liver Cancer. Blue Faery has three education and awareness programs: Love Your Liver, The Truth About Liver Cancer, and You and Liver Cancer.

AstraZeneca funded this year's award.

---
Press release service and press release distribution provided by https://www.24-7pressrelease.com
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.